N-NOSE is a cancer screening test takes advantage of the keen olfactory sensors of nematodes. The test has been available to the public in Japan in January 2020.
The world's first biological ”diagnostic” technology.
At Hirotsu Bio Science, we contribute to the development of revolutionary disease diagnostic technologies to lessen your concerns over health.
Health is the foundation of a fulfilling life. When the body is healthy, the mind naturally becomes positive and optimistic. At Hirotsu Bio Science, we are committed to developing revolutionary disease diagnostic technologies that help alleviate concerns about health and contribute to a society where people can live with peace of mind.
Conventional medical diagnostics have primarily relied on man-made devices, where achieving both high sensitivity and low costs has long been a challenge. The concept of biological diagnostics offers a breakthrough. By harnessing the remarkable capabilities of biology, biological diagnostics achieve levels of sensitivity beyond that of artificial devices, while keeping costs low by utilizing organisms that require no maintenance.
Based on this principle, Hirotsu Bio Science is advancing the world’s first practical application of biological diagnosis: the cancer test “N-NOSE.” This test is non-invasive, using only a urine sample, and offers multiple advantages including high sensitivity, affordability, and early detection. We are dedicated to accelerating research and development so that N-NOSE can reach society as quickly as possible.
Innovative science is born from the creativity and relentless effort of researchers. While the research environment in Japan has grown increasingly challenging in recent years, Hirotsu Bio Science places research and development at the core of our corporate philosophy. We aspire to be a company where researchers can fully demonstrate their abilities and play a leading role in shaping the future.